Sunshine Lake Pharma Co., Ltd.

Research Sunshine Lake Pharma Co., Ltd. (6887.HK) on Bullrun: market cap HKD 22.09B. Explore financials, valuation history, model signals, and stock context.

Key Metrics

Valuation Snapshot

latest market cap is HKD 22.09B.

Five-year financial history

YearRevenueNet incomeFree cash flowGross marginDiluted EPSCashTotal debtEquity
FY2025CNY 4.82BCNY 272.44MCNY 228.28M76.5%n/aCNY 1.49BCNY 4.68BCNY 4.34B
FY2024CNY 4.02B-CNY 207.43M-CNY 724.67M76.1%-0.46CNY 1.48BCNY 4.62BCNY 344.15M
FY2023CNY 6.39BCNY 184.92MCNY 782.88M79.5%0.41CNY 1.92BCNY 5.35BCNY 327.92M
FY2022CNY 3.81B-CNY 1.21BCNY 143.73M76.6%-2.65CNY 971.51MCNY 6.28B-CNY 3.69B

Valuation history

YearSnapshot dateMarket capP/EDividend yieldAnnual dividend/share
20262026-10-18HKD 22.09Bn/an/a0

Dividend history

Latest trailing dividend snapshot: annual dividend/share 0 HKD.

About Sunshine Lake Pharma Co., Ltd.

Sunshine Lake Pharma Co., Ltd. engages in the research, development, manufacture, and sale of pharmaceutical products for the treatment of infectious diseases, chronic diseases, and oncology. It offers Kewei for the treatment of influenza; Dongweien and Dongyinghe for the treatment of hepatitis C. The company also engages in the import, export, wholesale, retail, and distribution of pharmaceutical products, intermediates, and active pharmaceutical ingredients; product quality inspection;

Related stock research

Other Healthcare stocks

Frequently asked questions

What is Sunshine Lake Pharma Co., Ltd.'s market cap?

Sunshine Lake Pharma Co., Ltd.'s market capitalization is HKD 22.09B.

What does Sunshine Lake Pharma Co., Ltd. do?

Sunshine Lake Pharma Co., Ltd. engages in the research, development, manufacture, and sale of pharmaceutical products for the treatment of infectious diseases, chronic diseases, and oncology. It offers Kewei for the treatment of influenza; Dongweien and Dongyinghe for the treatment of hepatitis C.